Symbols

GMAB

Genmab·NASDAQ

--(--)

Signals Analysis

Bullish signal 6

Bearish signal 2

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Significant Net Income Decline

High Cash/net Profit Ratio

Revenue Beats Expectation

EPS Beats Expectation

Bearish Abandoned Baby

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About GMAB

Genmab A/S

An international biotechnology company focused on creating and developing innovative antibody therapeutics

Industry

Pharmaceutical

Established Date

06/11/1998

Listing Date

07/18/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

3,029

Fiscal Year Ends

12-31

Website

www.genmab.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

Carl Jacobsens Vej 30, 2500 Valby, Denmark

Business

Introduction

Genmab A/S was incorporated on June 11, 1998. The Company is an international biotechnology company with a portfolio of novel antibody-based products and product candidates designed to meet the medical needs of patients with cancer and other serious diseases and improve their treatment outcomes. The company's goal in establishing its product line is to bring drugs to market in geographic areas where they believe they can maximize their value and have a meaningful impact on the therapeutic field.

Company Financials

EPS

GMAB has released its 2025 Q3 earnings. EPS was reported at 0.65, versus the expected 0.47, beating expectations. The chart below visualizes how GMAB has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

GMAB has released its 2025 Q4 earnings report, with revenue of 1.06B, reflecting a YoY change of 14.63%, and net profit of 31.00M, showing a YoY change of -94.38%. The Sankey diagram below clearly presents GMAB's revenue sources and cost distribution.